Mon.Jan 13, 2025

article thumbnail

Five Interesting Things To Know About Sulopenem (Orlynvah)

IDStewardship

In this article an infectious diseases pharmacist discusses five interesting things to know about sulopenem (Orlynvah). Authored by: Tina Zheng, Pharm.D., BCIDP UNDER CONSTRUCTION Article PostedXXX Sulopenem etzadroxil and probenecid (Orlynvah) was recently approved in October 2024 for the treatment of uncomplicated urinary tract infections (uUTI) caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis.

Packaging 130
article thumbnail

STAT+: J&J to buy Intra-Cellular Therapies for $14.6B, picking up mental health drug

STAT

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will provide a boost as the industry gathers for one of its largest events of the year. With the acquisition, the pharma giant will get Intra-Cellular’s Caplyta, which is approved to treat schizophrenia and bipolar-related depression.

139
139
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medicare Drug Pricing Reform Brings Financial Relief to Patients

Pharmacy Times

The new Medicare cap limits out-of-pocket drug costs to $2000 annually.

139
139
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

As deadly fires continue to rage in Los Angeles, healthcare companies far and wide are stepping up to serve those affected. At least 24 people have died from the fires and dozens remain missing.

136
136
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: Truveta enlists health systems, drugmakers to launch ambitious new genomic database

STAT

Health data company Truveta said Monday it’s partnering with health systems and drugmakers to launch the Truveta Genome Project , a database of genetic data that is expected to accelerate personalized medicine and help discover new drugs.  Truveta plans to use leftover biospecimens from patients — after they consent — receiving routine health care at participating health systems to create the database.

article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

A recent confluence of events marks the first time in decades that there's been indication of real, meaningful change to the system, writes Blue Shield of California's Matthew Gibbs.

128
128

More Trending

article thumbnail

Q&A: How Specific GLP-1s Impact Different Patient Populations | ASHP Midyear

Drug Topics

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.

112
112
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

Though largely comprised of nurses, the walk-off that began Friday also includes physician associates and doctorsthe latter of which is a first for Oregon, per the Oregon Nurses Association.

111
111
article thumbnail

JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic

Pharmaceutical Technology

NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.

article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

The pending purchase values Access Healthcare at roughly $2 billion, per Bloomberg, and builds on the private equity firm's recent revenue cycle management dealmaking.

111
111
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Pharmalittle: We’re reading about J&J and GSK deals, a departing FDA official, and more

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine of deadlines, online meetings, and the like has predictably returned. Of course, some folks have a more challenging re-entry if they are attending the J.P. Morgan Healthcare Conference, a sort of Woodstock for investors.

FDA 110
article thumbnail

GSK confirms plan to buy cancer firm IDRx for $1bn

pharmaphorum

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

103
103
article thumbnail

Challenges Pharmacists May Face When Implementing CGM Counseling

Drug Topics

A conversation with Heather Folz, PharmD, BCACP and Christina H. Sherrill, PharmD, BCACP, BC-ADM.

98
article thumbnail

Will compounded semaglutide be banned?

The Checkup by Singlecare

A compounded medication is a custom formulation of an existing brand-name or generic drug made by a licensed pharmacist and designed to meet a patients unique needs. For example, a person who is allergic to a common dye included in a prescription drug could have a compounded version of the drug made without that dye. More notably, compounded drugs are also made to counteract drug shortages.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Q&A: A Pharmacist’s Career Journey to Becoming a Nutritionist

Drug Topics

Sarah Gray, PharmD, GAICD, discussed her experience as a pharmacist who added nutrition counseling to her clinical expertise.

98
article thumbnail

Nine-month-old obesity player Metsera files an IPO

pharmaphorum

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.

98
article thumbnail

Many US Adults Remain Unaware of Available Pharmacy Services

Drug Topics

Rite Aid recently released a survey detailing US patients perspective of how they engage with their pharmacists.

98
article thumbnail

Regeneron, Illumina join $320m Truveta investment

pharmaphorum

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

96
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Nonopioid Combination More Effective Than Opioids at Managing Postsurgical Pain

Drug Topics

A combination of ibuprofen and acetaminophen was found to be superior to hydrocodone and acetaminophen in managing pain after impacted mandibular third-molar extraction surgery.

98
article thumbnail

Zepbound vs. Mounjaro: Compare effectiveness, coverage, side effects, and costs

The Checkup by Singlecare

If you or someone you know experiences weight-related challenges or Type 2 diabetes, medications like Zepbound and Mounjaro might be part of the conversation when it comes to treatment options. These medications both involve a weekly injection and share the same active ingredient, tirzepatide. As a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide can help control appetite and decrease sugar levels.

article thumbnail

Pharmacists Are Critical to Proper Management of IVIG for Chronic Inflammatory Demyelinating Polyneuropathy

Pharmacy Times

Managing comorbidities, ensuring proper dosing, and treating IVIG-related adverse events are areas where pharmacists play a large role.

91
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

The two companies will co-develop and deploy integrated AI-driven products that address needs across predictive and personalized care, interoperability, efficiency, diagnostics and patient engagement.

89
article thumbnail

STAT+: Cigna, Centene, Walgreens drop out of J.P. Morgan conference

STAT

SAN FRANCISCO — Cigna and Centene have bowed out of this year’s J.P. Morgan Healthcare Conference, a possible sign that leaders of large health care companies are looking to avoid public appearances in light of the assassination of a high-profile executive last month. The health insurance giants are among 11 major companies that dropped out of the industry’s main investor event, according to the final agenda posted by J.P.

Insurance 144
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

SCAN Group will make a strategic investment in Cresta, which has built a generative AI platform for contact centers, the insurer told Fierce Healthcare exclusively.

article thumbnail

ASHP Midyear: Expert Discusses the GLP-1 Landscape for Diabetes Care

Pharmacy Times

Pharmacy Times interviews Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, about glucagon-like peptide-1 receptors for diabetes treatment.

81
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

The AI task force will release a report on AI-powered ambient scribes and revenue cycle management tools in the first quarter. A goal of the report is to provide guidance to healthcare organizations on how to track the efficacy of the tools.

81
article thumbnail

FDA Grants Breakthrough Therapy Designation to GSK’227 to Treat Osteosarcoma

Pharmacy Times

The designation was supported by data from the phase 2, open-label, randomized, multi-center ARTEMIS-002 clinical trial, which assessed the safety and efficacy of GSK227.

article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

The 16-hospital system stressed that it isn't going out of business, but is using the bankruptcy process to streamline much-needed divestitures. The company was recently in the crosshairs of a bipartisan Senate report critical of longtime private equity owner, Leonard Green & Partners.

article thumbnail

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

pharmaphorum

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

75
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

Under this program, Advocate Health intends to "rewire" its operations as it looks to the future of healthcare, CEO Eugene Woods said during a session at the J.P. Morgan Healthcare Conference on Monday.

78
article thumbnail

STAT+: GSK to buy cancer-focused IDRx in $1 billion deal

STAT

LONDON — Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront. The deal, which includes another $150 million in milestone payments, gives GSK an experimental treatment for a rare gastrointestinal cancer.  The announcement comes as much of the biopharma world gathers in San Francisco for the J.P.

130
130
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

Rock Health's annual report outlines key trends in VC funding: a handful of large, more established players dominated healthcare innovation headlines, heavyweight investors drove sector dealmaking and digital health startups turned to M&A to build out their offerings.

78
article thumbnail

Telehealth Follow-Up Appointments Effective Alternative to Maintaining Asthma Disease Control

Pharmacy Times

Virtual appointments were also an accessible alternative to in-person visits for patients who face obstacles accessing asthma care.

73